# Safinamide

## Equfina 50mg

| TAH Drug Code      | [OEQU](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OEQU)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Improve the wearing-off phenomenon of Parkinson's disease treated with preparations containing levodopa.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Dosing             | Parkinson disease: Oral 50 mg once daily (in combination with carbidopa/levodopa); after 2 weeks may increase to 100 mg once daily (in combination with carbidopa/levodopa) based on response and tolerability. Discontinuation of therapy: Decrease dose to 50 mg for one week before discontinuing therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Hypersensitivity to safinamide or any component of the formulation. Severe hepatic impairment (Child-Pugh class C) Concomitant use with drugs in MAOI class or drugs that are potent inhibitors of monoamine oxidase， including linezolid; increased risk of elevated blood pressure， including hypertensive crisis. Concomitant use of opioids (eg， meperidine and its derivatives， methadone， propoxyphene， or tramadol)， serotonin-norepinephrine reuptake inhibitors (SNRIs)， tricyclic antidepressants， tetracyclic antidepressants， triazolopyridine antidepressants， cyclobenzaprine， methylphenidate and its derivatives， amphetamine and its derivatives， or St John’s wort; increased risk of life-threatening serotonin syndrome. Concomitant use of dextromethorphan; increased risk of psychosis or abnormal behavior. Albinism， retinal degeneration， uveitis， inherited retinopathy or any active retinopathy (including severe progressive diabetic retinopathy). |
| Adverse Effects    | Common: Nausea (3-6%)， Dyskinesia (17-21%)， Insomnia (1-4%)， Falls (4-6%) Serious: Hypertension (5-7%)， Hallucinations， Impulse control disorder， Serotonin syndrome >10%: Dyskinesia (17-21%) 1-10%: Cardiovascular: Hypertension (including exacerbation of hypertension: 5-7%)， orthostatic hypotension (2%)， Dyspepsia (2%)， nausea (6%)， Increased serum alanine aminotransferase (5-7%)， increased serum aspartate aminotransferase (6-7%)， Anxiety (2%)， falling (6%)， insomnia (4%)， Cough (2%) Frequency not defined: Nervous system: Impulse control disorder， sudden onset of sleep Postmarketing: Hypersensitivity reaction， Headache                                                                                                                                                                                                                                                                                                                                 |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| More Info          | [UpToDate](https://www.uptodate.com/contents/safinamide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

